Lexicon Genetics Announces Webcast of Investor / Analyst Day Presentation

Apr 12, 2001, 01:00 ET from Lexicon Genetics Incorporated

    THE WOODLANDS, Texas, April 12 /PRNewswire/ --
 Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that its
 presentation at the Company's Investor / Analyst Day will be webcast live over
 the Internet and may be viewed by accessing Lexicon's corporate website at
 www.lexicon-genetics.com.
     Lexicon senior management will provide an overview of the Company.  The
 presentation will be delivered at 6:30 p.m. (Central Time) on Wednesday,
 April 18th from Lexicon's corporate headquarters in The Woodlands, Texas.
 Following the webcast, an archived version of the presentation will be
 available until April 20th on Lexicon's corporate website under the "Investor
 Relations" tab.
     Lexicon Genetics Incorporated is a leader in defining the functions of
 genes for drug discovery.  Lexicon uses its patented gene targeting knockout
 technology and its high-throughput genome-wide gene trapping technology to
 discover thousands of genes and expand its OmniBank(R) library of more than
 100,000 knockout clones.  The Company uses an integrated platform of
 functional genomics technologies to accelerate large-scale analysis of
 mammalian gene function for drug discovery.  Through Lexicon's corporate
 website, www.lexicon-genetics.com, researchers worldwide can access the
 OmniBank library and form collaborations with Lexicon to discover
 pharmaceutical products based on genes and knowledge of their functions.
 Lexicon has established drug discovery alliances with major pharmaceutical and
 biotechnology companies as well as leading academic institutions worldwide.
     Statements in this release relating to Lexicon that are not historical
 facts or information are "forward-looking statements" within the meaning of
 the Private Securities Litigation Reform Act of 1995.  Such forward-looking
 statements are based on management's current assumptions and expectations.
 Such forward-looking statements involve risks, uncertainties and other
 important factors, specifically including those relating to Lexicon's ability
 to enforce its patents, that may cause the actual results of Lexicon to be
 materially different from any future results expressed or implied by such
 forward-looking statements, and there can be no assurance that actual results
 will not differ materially from management's expectations.  Information
 identifying such important factors is contained under "Factors Affecting
 Forward-Looking Statements" and "Business - Risk Factors" in our annual report
 on Form 10-K for the year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  Lexicon undertakes no obligation to
 update any such forward-looking statements.
 
 

SOURCE Lexicon Genetics Incorporated
    THE WOODLANDS, Texas, April 12 /PRNewswire/ --
 Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that its
 presentation at the Company's Investor / Analyst Day will be webcast live over
 the Internet and may be viewed by accessing Lexicon's corporate website at
 www.lexicon-genetics.com.
     Lexicon senior management will provide an overview of the Company.  The
 presentation will be delivered at 6:30 p.m. (Central Time) on Wednesday,
 April 18th from Lexicon's corporate headquarters in The Woodlands, Texas.
 Following the webcast, an archived version of the presentation will be
 available until April 20th on Lexicon's corporate website under the "Investor
 Relations" tab.
     Lexicon Genetics Incorporated is a leader in defining the functions of
 genes for drug discovery.  Lexicon uses its patented gene targeting knockout
 technology and its high-throughput genome-wide gene trapping technology to
 discover thousands of genes and expand its OmniBank(R) library of more than
 100,000 knockout clones.  The Company uses an integrated platform of
 functional genomics technologies to accelerate large-scale analysis of
 mammalian gene function for drug discovery.  Through Lexicon's corporate
 website, www.lexicon-genetics.com, researchers worldwide can access the
 OmniBank library and form collaborations with Lexicon to discover
 pharmaceutical products based on genes and knowledge of their functions.
 Lexicon has established drug discovery alliances with major pharmaceutical and
 biotechnology companies as well as leading academic institutions worldwide.
     Statements in this release relating to Lexicon that are not historical
 facts or information are "forward-looking statements" within the meaning of
 the Private Securities Litigation Reform Act of 1995.  Such forward-looking
 statements are based on management's current assumptions and expectations.
 Such forward-looking statements involve risks, uncertainties and other
 important factors, specifically including those relating to Lexicon's ability
 to enforce its patents, that may cause the actual results of Lexicon to be
 materially different from any future results expressed or implied by such
 forward-looking statements, and there can be no assurance that actual results
 will not differ materially from management's expectations.  Information
 identifying such important factors is contained under "Factors Affecting
 Forward-Looking Statements" and "Business - Risk Factors" in our annual report
 on Form 10-K for the year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  Lexicon undertakes no obligation to
 update any such forward-looking statements.
 
 SOURCE  Lexicon Genetics Incorporated